“Alnylam is focused on building a top-tier biopharmaceutical company, advancing RNAi therapeutics as a whole new class of medicines with transformative potential for patients around the world. This exciting new relationship with Blackstone brings us much closer to that goal, securing our bridge towards a self-sustainable financial profile that we believe can now be achieved with out any need for Alnylam to access the equity markets in the future,” said Alnylam CEO John Maraganore, Ph.D., in a statement.
Alnylam is a previous MSLC Tax Incentive Program awardee. The MLSC has continued to utilize the Tax Incentive Program to focus on leveraging diverse life sciences assets across the state to encourage job growth more equitably throughout Massachusetts.
